Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 8/20 | 0.49 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 2/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24210574 | 0.84 | AHR (0.50) | AHRCDK8TP53 | |
| SCHEMBL21638122 | 0.79 | AHR (0.54) | AHRARTP53TTR | |
| SCHEMBL29758533 | 0.79 | AHR (0.51) | AHRARTTR | |
| SCHEMBL23501856 | 0.79 | KMT2A (0.36) | AHRARTP53MEN1KMT2A | |
| SCHEMBL30729596 | 0.78 | AHR (0.50) | AHRARCCNCCDK8TP53 | |
| SCHEMBL26234620 | 0.78 | AHR (0.50) | AHRARCCNCCDK8TP53 | |
| SCHEMBL30729597 | 0.78 | AHR (0.50) | AHRARCCNCCDK8TP53 | |
| SCHEMBL31120338 | 0.77 | AHR (0.46) | AHRARCCNCCDK8TP53 | |
| SCHEMBL29828811 | 0.77 | AHR (0.56) | AHRCCNCCDK8TTR | |
| SCHEMBL27282397 | 0.76 | AHR (0.49) | AHRARCCNCCDK8TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114829356-B | Heterocyclic compound and organic light-emitting component comprising same | LT素材株式会社 | 2024-07-19 | — | — | CN | disclosed |
| US-20230115080-A1 | HETEROCYCLIC COMPOUND, AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2023-04-13 | — | — | US | disclosed |
| EP-4074705-A1 | HETEROCYCLIC COMPOUND, AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LT Materials Co., Ltd. (KR) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021118159-A1 | HETEROCYCLIC COMPOUND, AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | 엘티소재주식회사 | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115080-A1 | HETEROCYCLIC COMPOUND, AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | CRY1, CRY2, CYP1A1 | AHR 30/4885AR 1170/4885CCNC 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.